Lower levels of hemoglobin and a loss of hemoglobin are associated with a statistically significant and clinically meaningful decrement in health utility in post-menopausal women.
The purpose of our study was to use health related quality of life data from the Women's Health Initiative (WHI) to calculate health related utility weights and examine differences in these health utility weights across different hemoglobin levels.
A loss of hemoglobin has both economic and quality of life implications. But little data are available on how hemoglobin loss affects health utility - a measure of health-related quality of life commonly used in economic evaluations. A recent study, "Health Utilities Associated with Hemoglobin Levels and Blood Loss In Postmenopausal Women: The Women's Health Initiative", published in Value in Health used data from the Women's Health Initiative (WHI) to calculate health utility scores for varying levels of hemoglobin and examine the relationship between a loss in hemoglobin and a change in health utility in a population of post-menopausal women. The study was co-authored by Dr. Brooke Harrow currently of Vertex Pharmaceuticals, Dr. Charles B. Eaton and Mary Roberts of the Center for Primary Care and Prevention, Brown University, Drs. Annlouise Assaf and Xuemei Luo of Pfizer Inc., and Dr. Zhao Chen of University of Arizona.
Says Dr. Harrow "Our study provides estimates of health utility associated with different levels of hemoglobin which will be useful for future economic evaluations to assess cost-effectiveness of interventions to mitigate hemoglobin loss. Our study also demonstrates a statistically significant and clinically meaningful decrement in health utility among post-menopausal women with 2 gm/dL hemoglobin loss. These findings, consistent with previous studies, raise concerns about potential consequences associated with hemoglobin decrease and indicate a need for cost-effective treatments to mitigate hemoglobin loss. "
Source:
ISPOR
Комментариев нет:
Отправить комментарий